Full text is available at the source.
Abstract
Aripiprazole has an intrinsic dopamine agonist activity of 30%.
- It acts as a partial agonist on 5-HT (1A) receptors and an antagonist at 5-HT (2A) receptors.
- Controlled studies revealed effectiveness in managing acute relapse of schizophrenic psychosis and chronic disorders.
- Aripiprazole successfully treats both productive psychotic and negative symptoms.
- Side effects include only slight changes in body weight and mild extrapyramidal symptoms, without prolactin elevation or significant QTc interval changes.
- Long-term efficacy in treating schizophrenia appears comparable to other antipsychotics like olanzapine.
- Initial evaluations suggest significant efficacy in treating mania in patients with bipolar disorders.
Simplified